Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins

This study tests whether combining two immunotherapy drugs, nivolumab and relatlimab, can shrink or control advanced solid tumors with a specific genetic feature (MSI-H) that have stopped responding to prior PD-(L)1 therapy. About 38 adults with these hard-to-treat cancers will r…

This study looked at whether adding the drug vorinostat to standard chemotherapy before surgery helps shrink tumors more in women with HER2-negative breast cancer. About 68 women took part, receiving either chemo alone or chemo plus vorinostat. The goal was to see if the combinat…

This study was designed to test the safety and effectiveness of giving the targeted drug adagrasib, alone or with the immunotherapy nivolumab, before surgery to people with a specific type of lung cancer (KRAS G12C mutation). The goal was to see if these drugs could shrink or eli…

This early-stage study tests whether giving immunotherapy drugs (nivolumab alone or with relatlimab) before and after surgery is safe and helps patients with liver cancer that can be removed. About 31 adults with resectable liver cancer will receive the drugs, then undergo surger…

This study tests whether giving a higher radiation dose to a specific brain area (the subventricular zone) alongside standard radiation and chemotherapy can delay glioblastoma from coming back. About 60 adults with newly diagnosed glioblastoma will be randomly assigned to receive…

This study tested giving immunotherapy drugs (nivolumab alone or with ipilimumab) before surgery to people with early-stage non-small cell lung cancer. The goal was to see if it is safe and can shrink tumors before removal. 39 participants received treatment, and researchers look…

This study tested whether giving a mix of hormone therapy, a targeted drug (palbociclib), and an immunotherapy (avelumab) before surgery could shrink early-stage estrogen receptor-positive breast tumors. About 33 adults with stage II-III breast cancer took part. The goal was to s…

This study tests whether adding a new drug (LY2157299) to the standard treatment enzalutamide can help men with advanced prostate cancer that has stopped responding to other treatments. About 60 participants will be randomly assigned to receive either the combination or enzalutam…

This early-phase study tests a vaccine targeting mutant KRAS proteins, combined with two immunotherapy drugs (nivolumab and ipilimumab), in 27 patients with resected pancreatic or colorectal cancer. The goal is to see if the combination is safe and boosts the immune system's abil…

This early-phase trial is testing whether giving immunotherapy drugs (nivolumab alone or with relatlimab) before standard chemoradiation is safe and feasible for people with operable stage II/III esophageal or gastroesophageal junction cancer. The study involves 32 participants a…

This study tests whether adding targeted radiation to the immunotherapy drug nivolumab (alone or with another drug, relatlimab) can help control advanced stomach, esophageal, or gastroesophageal junction cancer. About 21 adults with limited metastatic disease will receive radiati…

This study tests whether adding urelumab to nivolumab (both immunotherapy drugs) before bladder removal surgery improves the immune response against muscle-invasive bladder cancer. It includes 15 patients who either cannot receive standard chemotherapy due to health reasons or ch…

This study tests a combination of three drugs (paclitaxel, pembrolizumab, and olaparib) in people with advanced stomach cancer that has worsened after one prior treatment. The goal is to see if this mix is safe and helps patients live longer. About 36 adults with good organ funct…

This study tests whether continuing the targeted therapy palbociclib while switching to a different hormone therapy (fulvestrant) can help people with a certain type of advanced breast cancer (hormone receptor-positive, HER2-negative) whose disease has worsened despite initial tr…

This study tests different combinations of immunotherapy drugs given before and after surgery for pancreatic cancer that can be removed. About 76 participants will receive these treatments to see if they help the immune system fight the cancer better. The goal is to improve how p…

This early-stage trial tests the safety of combining an immunotherapy drug (nivolumab) with or without precise radiation (stereotactic radiosurgery) in 21 people with chordoma that has returned or spread. The goal is to see if this combination can help control the tumor with mana…

This study enrolls healthy relatives of patients with advanced HPV16-related cancer. Donors receive a therapeutic HPV vaccine to boost their immune cells against the virus. Their blood cells are then used for a bone marrow transplant or immune cell infusion in the cancer patient.…

This study tests the drug olaparib in 51 men whose prostate cancer has returned after surgery and is at high risk of spreading. Olaparib works by blocking a repair process in cancer cells, and early studies suggest it may be more effective when given earlier in the disease. The m…

This study tests whether giving two drugs—nivolumab and BMS-986253—before surgery can safely shrink tumors in people with head and neck cancer. About 24 adults with HPV-negative squamous cell carcinoma will receive the combination before their planned surgery. The main goals are …

This study tests a combination of two chemotherapy drugs, gemcitabine and docetaxel, given directly into the bladder for people with early-stage bladder cancer who have not received standard BCG therapy. The goal is to see if this treatment can clear the cancer and keep it from c…

This early-phase trial tests whether immune cells from a relative can safely fight advanced HPV16-related cancers that have returned or spread. About 24 patients will receive either a bone marrow transplant or a special infusion of donor T cells. The goal is to see if these treat…

This early-phase study tests a new two-drug combination taken by mouth for people with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and understand side effects. Up to 35 participants will be enrolled.

This early-phase study tests whether the drug itacitinib can prevent cytokine release syndrome (a severe inflammatory reaction) and reduce the need for long-term immune-suppressing medications after a stem cell transplant. The trial involves 32 older adults (age 60+) with certain…

This early-stage trial is testing whether combining two immunotherapy drugs with a precise, high-dose radiation treatment is safe and might help control recurrent glioblastoma, a very aggressive brain cancer. The study involves about 16 patients whose cancer has returned after in…

This study tests a special PET/CT scan that targets a protein (PSMA) on prostate cancer cells to see if it can better detect aggressive prostate cancer compared to the standard PSA blood test. About 150 men with elevated PSA levels will receive the scan before their routine prost…

This early-phase study tests a new type of proton therapy called Pro-GRID for people with large tumors (over 7 cm) that are hard to treat. The goal is to see if the treatment is safe and can be delivered successfully. The study involves 11 adults with sarcoma or melanoma, and foc…

This study aimed to collect prostate tissue samples from men undergoing brachytherapy for prostate cancer. The goal was to bank these samples for future research on how radiation affects the prostate. However, the study was withdrawn before enrolling any participants.

This study explores whether advanced MRI scans can detect how prostate cancer and nearby healthy tissues respond to radiation therapy while treatment is still ongoing. Researchers will enroll 38 men with prostate cancer who are scheduled for external beam radiation. The goal is t…